0.7001

5.05% -0.0372

Aldeyra Therapeutics Inc (ALDX)

Overview News Price History Option Chain Financials Discussions Forecast

Aldeyra Therapeutics Inc stock is traded at $0.7001, with a volume of 1.81M. It is down -5.05% in the last 24 hours and down -48.90% over the past month. Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Previous Close:

$0.7373

Open:

$0.74

24h Volume:

1.81M

Relative Volume:

0.70

Market Cap:

$42.23M

Revenue:

Net Income/Loss:

$-27.37M

P/E Ratio:

-1.538

EPS:

-0.4552

Net Cash Flow:

$-25.99M

1W Performance:

-23.59%

1M Performance:

-48.90%

6M Performance:

-61.11%

1Y Performance:

-87.01%

1-Day Range:

$0.6501

$0.74

1-Week Range:

$0.6501

$0.94

52-Week Range:

$0.6501

$5.93

Aldeyra Therapeutics Inc Stock (ALDX) Company Profile

Name

Aldeyra Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

781-761-4904

Address

131 HARTWELL AVENUE, LEXINGTON, MA

Employee

Twitter

@aldeyraaldx

Next Earnings Date

2026-11-04

Latest SEC Filings

ALDX's Discussions on Twitter

Compare ALDX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALDX Aldeyra Therapeutics Inc	0.7001	42.23M	0	-27.37M	-25.99M	-0.4552
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform
Apr-02-24	Resumed	H.C. Wainwright	Buy
Apr-27-22	Resumed	H.C. Wainwright	Buy
Feb-08-21	Initiated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Oct-30-20	Initiated	Jefferies	Buy
Oct-16-20	Initiated	BTIG Research	Buy
Sep-22-20	Initiated	Alliance Global Partners	Buy
May-12-20	Initiated	Oppenheimer	Outperform
Dec-04-18	Initiated	Citigroup	Buy
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy
Sep-26-16	Initiated	H.C. Wainwright	Buy
Jul-01-16	Initiated	Stifel	Buy
Jul-01-15	Initiated	Canaccord Genuity	Buy
Mar-25-15	Initiated	Chardan Capital Markets	Buy
Mar-20-15	Reiterated	H.C. Wainwright	Buy
Nov-18-14	Initiated	H.C. Wainwright	Buy
Jun-19-14	Initiated	Aegis Capital	Buy

View All

Aldeyra Therapeutics Inc Stock (ALDX) Latest News

Oct 15, 2026

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research

Oct 15, 2026

Oct 14, 2026

Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research

Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research

Oct 14, 2026

Oct 12, 2026

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research

Oct 12, 2026

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research

Oct 12, 2026

Oct 09, 2026

argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research

Oct 09, 2026

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research

Oct 09, 2026

Oct 08, 2026

Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research

Oct 08, 2026

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research

Oct 08, 2026

Oct 07, 2026

ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research

Oct 07, 2026

Oct 06, 2026

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research

Oct 06, 2026

Oct 03, 2026

Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye - Streetwise Reports

Oct 03, 2026

Sep 30, 2026

Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG - Moomoo

Sep 30, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire

Sep 30, 2026

H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target - Investing.com

Sep 30, 2026